Program
HS-10380
A development code. Also written as “HS-10380 Low Dose”, “HS-10380 Medium dose” and “HS-10380 High Dose”.
Its studies are mostly in Schizophrenia, led by Hansoh Pharmaceutical Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hansoh Pharmaceutical Group | 53 open or running | phase 3since Aug 7, 2026 | Jul 5, 2022 | Jul 31, 2028phase 3 · NCT07759869 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 5, 2022First study: phase 1 study in SchizophreniaFirst studyNCT05480592 · 76 enrolled · China
- Jul 10, 2023Phase 2 study in SchizophreniaNCT05964790 · 112 planned
- Apr 9, 2026Phase 2 study in SchizophreniaNCT07550387 · 363 enrolled · China
- Aug 7, 2026Phase 3 study in SchizophreniaPhase 3 reachedNCT07759869 · 500 planned · China
- Oct 28, 2026Phase 3 study in SchizophreniaNCT07911787 · 476 planned · China
Ahead
- Jul 31, 2028Primary completion: phase 3 study in SchizophreniaNCT07759869
- Jan 24, 2029Primary completion: phase 3 study in SchizophreniaNCT07911787
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07911787Schizophrenia · China | 3 | Not yet recruiting | Jan 24, 2029 | 476 |
| NCT07759869Schizophrenia · China | 3 | Not yet recruiting | Jul 31, 2028 | 500 |
| NCT07550387Schizophrenia · China | 2 | Completed | Jan 2, 2026 | 363 |
| NCT05964790Schizophrenia | 2 | Not yet recruiting | Jun 30, 2024 | 112 |
| NCT05480592Schizophrenia · China | 1 | UNKNOWN | Jun 30, 2023 | 76 |
How it is read
Names in the registry
- “HS-10380”, 4 entries
- “HS-10380 Low Dose”, 1 entry
- “HS-10380 Medium dose”, 1 entry
- “HS-10380 High Dose”, 1 entry
Codes read as this program: HS10380.
Conditions, from the studies’ own filings
- Schizophrenia, 5 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.